Structure―activity relationship of a series of non peptidic RGD integrin antagonists targeting α₅β₁: Part 2DELOUVRIE, Benedicte; AL-KADHIMI, Katherine; JUDE, David A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4117-4121, issn 0960-894X, 5 p.Article

Structure―activity relationship of a series of non peptidic RGD integrin antagonists targeting α₅β₁: Part 1DELOUVRIE, Bénédicte; AL-KADHIMI, Katherine; JUDE, David A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4111-4116, issn 0960-894X, 6 p.Article

ZD6474, a potent inhibitor of Vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activityWILLIAMS, Kaye J; TELFER, Brian A; BRAVE, Sandra et al.Clinical cancer research. 2004, Vol 10, Num 24, pp 8587-8593, issn 1078-0432, 7 p.Article

Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenograftsCHECKLEY, David; TESSIER, Jean J. L; WEDGE, Stephen R et al.Magnetic resonance imaging. 2003, Vol 21, Num 5, pp 475-482, issn 0730-725X, 8 p.Article

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted TherapySMITH, Neil R; BAKER, Dawn; WEDGE, Stephen R et al.Clinical cancer research (Print). 2013, Vol 19, Num 24, pp 6943-6956, issn 1078-0432, 14 p.Article

Inhibitors of epidermal growth factor receptor tyrosine kinase : Optimisation of potency and in vivo pharmacokineticsBALLARD, Peter; BRADBURY, Robert H; WILLIAMS, Emma J et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 18, pp 4908-4912, issn 0960-894X, 5 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapiesKENDREW, Jane; ODEDRA, Rajesh; LOGIE, Armelle et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 4, pp 1021-1032, issn 0344-5704, 12 p.Article

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains : Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F. A; BALLARD, Peter; ROSS, Helen S et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 10, pp 2672-2676, issn 0960-894X, 5 p.Article

Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F; STOKES, Elaine S. E; THOMAS, Andrew P et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 6, pp 1300-1312, issn 0022-2623Article

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationWEDGE, Stephen R; OGILVIE, Donald J; GRAHAM, George A et al.Cancer research (Baltimore). 2002, Vol 62, Num 16, pp 4645-4655, issn 0008-5472Article